AG
TRML

Algert Global’s Tourmaline Bio TRML Stock Holding History

Algert Global’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,112
Closed -$311K – 1342
2024
Q3 		$311K Sell
12,112
-27,754
-70% -$463K 0.01% 993
2024
Q2 		$513K Buy
39,866
+21,965
+123% +$353K 0.02% 904
2024
Q1 		$410K Buy
+17,901
New +$631K 0.02% 815

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Algert Global's TRML Position: Q4 2024 in Review

Algert Global sold out of Tourmaline Bio (TRML) in Q4 2024, closing a stake of 12,112 shares — an estimated $311K sold.

Algert Global first reported a position in TRML in Q1 2024 and held it in 3 quarters. The position peaked at $513K in Q2 2024. 101 funds tracked by Wall St. Rank hold TRML as of Q4 2024.

  • Algert Global reported no remaining Tourmaline Bio position as of Q4 2024 after selling out during the quarter.
  • Algert Global sold 12,112 Tourmaline Bio shares in Q4 2024, an estimated $311K.
  • Algert Global first reported a position in Tourmaline Bio in Q1 2024 and held it in 3 quarters.
  • Algert Global's Tourmaline Bio position peaked at $513K in Q2 2024.
  • 101 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2024.

Based on Algert Global's 13F filing for Q4 2024, filed 14 Feb 2025.